Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Rev Med Inst Mex Seguro Soc ; 58(Supl 2): S246-259, 2020 09 21.
Article in Spanish | MEDLINE | ID: mdl-34695337

ABSTRACT

Coronaviruses are a family of viruses present in different species of animals, which can infect humans, causing epidemics and pandemics. On January 9th, 2020, a new virus was announced as the cause of an outbreak of severe pneumonia in Wuhan, China. On March 11th, WHO declared the SARS-CoV-2 pandemic, the disease was called COVID-19. The virus is transmitted by droplets, contact and airborne during aerosol-generating procedures. In almost all pediatric cases a household contact was the source of infection. Unlike adults, the disease in children has a mild course, even in those under one year of age. The main symptoms are fever, dry or productive cough, headache, general discomfort, and shortness of breath, which is a sign of severity. The incubation period is 1-12.5 days (media 5-6 days). The most affected age group are school children. The disease may present as a mild acute upper airway infection, or as pneumonia. Very few cases progress to severe pneumonia and other complications such as acute respiratory distress syndrome, shock and multiorgan failure. There is not yet a specific antiviral treatment approved for use in children. This document aims to guide the management of suspected or confirmed pediatric patients of COVID-19.


El 9 de enero de 2020 fue anunciado un nuevo virus como la causa de un brote de neumonía grave en Wuhan, China. El 11 de marzo, la Organización Mundial de la Salud declaró la pandemia por SARS-CoV-2, virus causante de la enfermedad COVID-19. El virus se transmite por gotas, contacto y por vía aérea en procedimientos que generan aerosoles. En el caso de los niños, la fuente de contagio casi siempre es un contacto intradomiciliario. En los pacientes pediátricos, la enfermedad tiene un curso leve, incluso en los menores de un año. Los principales síntomas son: fiebre, tos seca o productiva, cefalea, malestar general y dificultad respiratoria, que es un signo de gravedad. El período de incubación es de 1 a 12.5 días (media 5-6). El grupo de edad más afectado son los escolares. La enfermedad puede presentarse como un cuadro leve de infección aguda de vías aéreas superiores o como neumonía. Muy pocos casos progresan a neumonía grave y a complicaciones como síndrome de distrés respiratorio agudo, choque y falla multiorgánica. Aún no hay tratamiento antiviral específico aprobado para su uso en niños. El presente documento tiene como objetivo guiar el manejo de los pacientes pediátricos sospechosos o confirmados de COVID-19.

2.
Rev Invest Clin ; 71(4): 283-290, 2019.
Article in English | MEDLINE | ID: mdl-31448789

ABSTRACT

Background: Febrile neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. Objective: The objective of this study was to evaluate the clinical efficacy of the continuous versus intermittent infusion of piperacillin/tazobactam (TZP) in febrile neutropenic pediatric patients. Methods: This is a non-blinded randomized controlled clinical trial. Eligible group consisted of hemato-oncological patients with FN who were candidates to receive TZP. Patients were randomized to one of two groups: Group 1 received antibiotic treatment through intravenous intermittent infusion of TZP 300 mg/kg/day based on piperacillin, divided into four doses, not exceeding 16 g/day; Group 2 received an initial TZP loading dose of 75 mg/kg infusion over 30 min, and then a continuous infusion of TZP 300 mg/kg/day through central line with pump over 24 h. Results: There were 176 episodes that could be assessed, 100 in Group 1 and 76 in Group 2. There was no statistically significant difference in treatment failure in the experimental group (continuous infusion) compared with the intermittent group, 21% versus 13% (p = 0.15). The increase in the absolute risk reduction was 0.08% (95% confidence interval 0.12-0.30), and the number needed to treat was 12.4. One patient in each group died. Conclusions: There were no differences in fever resolution, clinical cure rate, or mortality when comparing the continuous with the intermittent TZP infusion.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Antineoplastic Agents/adverse effects , Febrile Neutropenia/drug therapy , Neoplasms/drug therapy , Piperacillin, Tazobactam Drug Combination/administration & dosage , Adolescent , Antineoplastic Agents/administration & dosage , Child , Child, Preschool , Drug Administration Schedule , Female , Humans , Infant , Infusions, Intravenous , Male
3.
Rev. invest. clín ; 71(4): 283-290, Jul.-Aug. 2019. tab, graf
Article in English | LILACS | ID: biblio-1289697

ABSTRACT

Abstract Background Febrile neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. Objective The objective of this study was to evaluate the clinical efficacy of the continuous versus intermittent infusion of piperacillin/tazobactam (TZP) in febrile neutropenic pediatric patients. Methods This is a non-blinded randomized controlled clinical trial. Eligible group consisted of hemato-oncological patients with FN who were candidates to receive TZP. Patients were randomized to one of two groups: Group 1 received antibiotic treatment through intravenous intermittent infusion of TZP 300 mg/kg/day based on piperacillin, divided into four doses, not exceeding 16 g/day; Group 2 received an initial TZP loading dose of 75 mg/kg infusion over 30 min, and then a continuous infusion of TZP 300 mg/kg/day through central line with pump over 24 h. Results There were 176 episodes that could be assessed, 100 in Group 1 and 76 in Group 2. There was no statistically significant difference in treatment failure in the experimental group (continuous infusion) compared with the intermittent group, 21% versus 13% (p = 0.15). The increase in the absolute risk reduction was 0.08% (95% confidence interval 0.12-0.30), and the number needed to treat was 12.4. One patient in each group died. Conclusions There were no differences in fever resolution, clinical cure rate, or mortality when comparing the continuous with the intermittent TZP infusion.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Febrile Neutropenia/drug therapy , Piperacillin, Tazobactam Drug Combination/administration & dosage , Anti-Bacterial Agents/administration & dosage , Neoplasms/drug therapy , Antineoplastic Agents/adverse effects , Infusions, Intravenous , Drug Administration Schedule , Antineoplastic Agents/administration & dosage
4.
Bol. méd. Hosp. Infant. Méx ; 74(1): 27-33, ene.-feb. 2017. tab, graf
Article in Spanish | LILACS | ID: biblio-888593

ABSTRACT

Resumen: Introducción: La tuberculosis (TB) continúa siendo un reto ya que las formas graves se presentan con mayor frecuencia en los menores de 5 años y el diagnóstico es complejo. El objetivo del presente trabajo fue describir las formas de presentación clínica, frecuencia, métodos de diagnóstico empleados y respuesta al tratamiento en niños con TB atendidos en un hospital de tercer nivel. Métodos: Se diseñó un estudio retrospectivo, descriptivo, de una cohorte de casos consecutivos atendidos desde enero de 2010 hasta diciembre de 2013. Se revisaron 93 expedientes clínicos de niños con diagnóstico de TB de acuerdo con la definición de la NOM-006-SSA2-2013. Se utilizó estadística descriptiva para el análisis. Resultados: El 58% de 93 niños fueron pacientes de sexo masculino con una media de edad de 7 años. El 97% contaba con antecedente de vacunación BCG; el 6% tuvo contacto con algún caso de TB. Las formas clínicas más frecuentes fueron la TB pulmonar (30.1%), ganglionar (24.7%), miliar/diseminada (16.1%), meníngea (13%) y ósea (7.5%). Los síntomas más comunes fueron fiebre y pérdida de peso (50% y 40%, respectivamente). El BAAR y el cultivo fueron positivos en el 26% y el 7% de todos los casos, respectivamente. El estudio histopatológico fue concluyente en el 90%. El tratamiento fue exitoso en el 94.6%, sin mortalidad asociada. Conclusiones: La asociación del cuadro clínico con las alteraciones en la radiografía de tórax y PPD positivo son útiles para establecer el diagnóstico presuntivo e iniciar el manejo oportuno.


Abstract: Background: Tuberculosis (TB) remains a challenge because severe forms occur most frequently in children under 5 years of age and the diagnosis is complex. The objective of this paper was to describe the clinical presentation, frequency, diagnostic methods used and response to treatment in children with TB treated at a tertiary level hospital. Methods: The study was retrospective and descriptive of a cohort of consecutive cases treated from January 2010 to December 2013. Ninety-three medical records of children diagnosed with TB according to the definition of the NOM-006-SSA2-2013 were reviewed. Descriptive statistics were used for the analysis. Results: From 93 children, 58% were male (mean age of 7 years), 97% with a history of BCG vaccination, and 6% had contact with a TB case. The most frequent clinical forms were pulmonary (30.1%), lymph node (24.7%), miliary/disseminated (16.1%), meningeal (13%), and osteal TB (7.5%). The most common symptoms were fever and weight loss (50% and 40%, respectively). BAAR and culture were positive in 26% and 7% of all cases, respectively. The histopathological study was conclusive in 90% of the cases. The treatment was successful in 94.6%, with not associated mortality. Conclusions: The association of clinical symptoms with alterations in chest radiography and positive PPD are useful in establishing the presumptive diagnosis and an early and appropriate treatment.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Tuberculosis/epidemiology , BCG Vaccine/administration & dosage , Weight Loss , Fever/epidemiology , Tuberculosis/diagnosis , Tuberculosis/therapy , Retrospective Studies , Cohort Studies , Treatment Outcome , Fever/microbiology , Tertiary Care Centers
5.
Bol Med Hosp Infant Mex ; 74(1): 27-33, 2017.
Article in Spanish | MEDLINE | ID: mdl-29364810

ABSTRACT

BACKGROUND: Tuberculosis (TB) remains a challenge because severe forms occur most frequently in children under 5 years of age and the diagnosis is complex. The objective of this paper was to describe the clinical presentation, frequency, diagnostic methods used and response to treatment in children with TB treated at a tertiary level hospital. METHODS: The study was retrospective and descriptive of a cohort of consecutive cases treated from January 2010 to December 2013. Ninety-three medical records of children diagnosed with TB according to the definition of the NOM-006-SSA2-2013 were reviewed. Descriptive statistics were used for the analysis. RESULTS: From 93 children, 58% were male (mean age of 7 years), 97% with a history of BCG vaccination, and 6% had contact with a TB case. The most frequent clinical forms were pulmonary (30.1%), lymph node (24.7%), miliary/disseminated (16.1%), meningeal (13%), and osteal TB (7.5%). The most common symptoms were fever and weight loss (50% and 40%, respectively). BAAR and culture were positive in 26% and 7% of all cases, respectively. The histopathological study was conclusive in 90% of the cases. The treatment was successful in 94.6%, with not associated mortality. CONCLUSIONS: The association of clinical symptoms with alterations in chest radiography and positive PPD are useful in establishing the presumptive diagnosis and an early and appropriate treatment.


Subject(s)
BCG Vaccine/administration & dosage , Fever/epidemiology , Tuberculosis/epidemiology , Weight Loss , Adolescent , Child , Child, Preschool , Cohort Studies , Female , Fever/microbiology , Humans , Infant , Male , Retrospective Studies , Tertiary Care Centers , Treatment Outcome , Tuberculosis/diagnosis , Tuberculosis/therapy
6.
Rev Med Inst Mex Seguro Soc ; 52 Suppl 2: S8-15, 2014.
Article in Spanish | MEDLINE | ID: mdl-24983563

ABSTRACT

BACKGROUND: Pandemic influenza A (H1N1) virus was first reported in April 2009. The aim of this study is to describe the clinical course of patients with influenza-like illness treated in a tertiary care pediatric hospital. METHODS: Cross-sectional analytical study, encompassing the period from April 2009 to March 2010. Clinical and demographic information was obtained from clinical records. Data analysis was carried out using descriptive statistics, using a univariate analysis with the chi-square test, the exact Fisher test, and the Mann-Whitney U test for quantitative variables. RESULTS: 240 patients were included, out of which 53.9 % were female; median age was 5 years. Sixty four cases (26.6 %) were confirmed, 38 % had and underlying condition, and 10 % had received the influenza vaccine. One hundred and sixteen patients (48 %) were hospitalized. With regard to mortality, 10 out of 64 confirmed cases died, 3 of the 86 of the disregarded cases, and 2 of 90 without a confirmatory test died (p < 0.05). The patients who died started antiviral treatment on day 7; conversely, those who survived started the treatment on day 4 (p < 0.05). CONCLUSIONS: Lethality was higher in patients with confirmed infection. Antiviral treatment within the first 48 hours was observed to be essential for patients with risk for the development of complications.


INTRODUCCIÓN: en abril de 2009 se informó por primera vez del virus pandémico de la influenza A H1N1. El objetivo del presente estudio es describir el curso clínico de los pacientes atendidos con enfermedad tipo influenza en un hospital pediátrico de tercer nivel. MÉTODOS: estudio transversal analítico que comprendió el periodo de abril de 2009 a marzo de 2010. La información clínica y demográfica se obtuvo de los expedientes clínicos. El análisis de los datos se llevó a cabo mediante estadística descriptiva e inferencial, para lo cual se aplicó análisis univariado mediante chi cuadrada, prueba exacta de Fisher y U de Mann-Whitney para las variables cuantitativas. RESULTADOS: se incluyeron 240 pacientes, 53.9 % del sexo femenino; la mediana de la edad fue de cinco años. Se confirmaron 64 casos (26.6 %), 38 % tenía enfermedad subyacente y 10 % había sido vacunado contra el virus de la influenza. Fueron hospitalizados 116 pacientes (48 %). Respecto a la mortalidad, 10 casos fallecieron de los 64 confirmados, tres de los 86 casos descartados y dos de los 90 que carecían de prueba confirmatoria (p < 0.05). Los pacientes que fallecieron iniciaron tratamiento antiviral el séptimo día; por su parte, los que no fallecieron iniciaron el tratamiento en el cuarto día (p < 0.05). CONCLUSIONES: la letalidad fue mayor en los pacientes con infección confirmada. Se observó que el tratamiento antiviral en las primeras 48 horas es esencial para los pacientes con riesgo para desarrollar complicaciones.


Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Pandemics , Child , Cross-Sectional Studies , Female , Humans , Influenza, Human/therapy , Male , Mexico/epidemiology , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...